Browse Health
Internist, Endocrinologist (diabetes, hormones)
16 years of experience


Education ?

Medical School
Universite Saint-Joseph (1996)
Foreign school

Awards & Distinctions ?

Wayne State University School Of Medicin
American Board of Internal Medicine

Affiliations ?

Dr. Sleilati is affiliated with 5 hospitals.

Hospital Affiliations



  • Detroit Receiving Hospital & University Health Center
    4201 Saint Antoine St, Detroit, MI 48201
    Top 50%
  • Detroit Receiving Hospital
  • Hutzel Hospital
  • Harper Hospital
  • Detroit Receiving
  • Publications & Research

    Dr. Sleilati has contributed to 2 publications.
    Title Efficacy and Safety of Pioglitazone in Treatment of a Patient with an Atypical Partial Lipodystrophy Syndrome.
    Date January 2008
    Journal Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

    OBJECTIVE: To evaluate the effectiveness and safety of pioglitazone therapy in a patient with an atypical presentation of partial lipodystrophy. METHODS: We present a case report and review the associated literature to put this case in perspective and explain its atypical features. RESULTS: A 40-year-old woman was referred because of uncontrolled diabetes and dyslipidemia, despite receiving a total daily dose of insulin of 300 U and combination therapy with a statin and a fibrate. On examination, the patient was found to have substantial central and abdominal fat deposition in conjunction with slender arms and legs. The addition of pioglitazone to her therapeutic regimen resulted in a dramatic improvement in glycemic control and in the dyslipidemia. During approximately a 2-year period, the patient's insulin dose was decreased and was ultimately discontinued. Considerable increases in weight and in waist circumference were observed during this period. Sequencing of candidate genes known to be associated with familial partial lipodystrophy, acquired partial lipodystrophy, and generalized lipodystrophy showed no genetic abnormalities. Magnetic resonance imaging confirmed the presence of significant visceral and subcutaneous abdominal fat deposition, in association with scant fat tissue in the extremities. Her weight decreased after discontinuation of the insulin therapy and institution of dietary counseling. CONCLUSION: Thiazolidinediones have been shown to be efficacious in syndromic lipodystrophies, such as familial partial lipodystrophy subtype 2. We report that these pharmaceutical agents may also help improve metabolic variables in atypical lipodystrophy syndromes with no obvious molecular basis. A pronounced weight gain might result from synergism between thiazolidinediones and insulin promoting adipogenesis, which diminished somewhat after discontinuation of insulin therapy.

    Title Acromegaly and Pheochromocytoma: Report of a Rare Coexistence.
    Date August 2002
    Journal Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

    OBJECTIVE: To describe a patient with the rare coexistence of acromegaly and pheochromocytoma. METHODS: We report a case of a 57-year-old woman, who was initially examined because of polyarthritis, she was also diagnosed with type 2 diabetes mellitus and hypertension at age 56 years. Her history, clinical findings, laboratory results, and management are summarized, and etiologic hypotheses are discussed. RESULTS: The patient had recurrent headaches and reported an increasing size of her shoes and gloves during the previous 4 years. Enlargement of her hands and feet and a bilateral temporal field defect were noted on examination. Laboratory studies revealed high levels of insulin-like growth factor I (IGF-I) and growth hormone (GH). Magnetic resonance imaging (MRI) showed a 3-cm sellar mass with impingement on the optic chiasm. The plasma level of growth hormone-releasing hormone (GHRH) was normal. She underwent transsphenoidal adenomectomy. Histologic examination confirmed a pituitary adenoma, immunoreactive for GH. Postoperatively, her headaches and arthritic pain diminished, and her levels of IGF-I and GH normalized; however, labile hypertension persisted. The urinary metanephrines and plasma catecholamines were increased. A 3-cm left adrenal mass, seen on abdominal MRI, was removed laparoscopically, after which urinary metanephrines normalized and both the diabetes and the hypertension resolved. Histopathologic analysis confirmed the diagnosis of pheochromocytoma. Immunohistochemical staining was negative for GHRH. CONCLUSION: The finding of a pheochromocytoma and acromegaly could be a fortuitous coexistence of two separate endocrine tumors; however, the probability of such an event is extremely low. A cause-and-effect relationship has been suggested because of previous reports of GHRH production by pheochromocytomas. Some investigators have also suggested that this coexistence might be a multiple endocrine neoplasia variant. Our patient had no evidence of GHRH production, nor did we document any familial autosomal dominant transmission pattern.

    Similar doctors nearby

    Dr. Silas Norman

    Internal Medicine
    36 years experience
    Detroit, MI

    Dr. James Brown

    Internal Medicine
    Detroit, MI

    Dr. David Stockton

    Internal Medicine
    20 years experience
    Detroit, MI

    Dr. Ruta Sharangpani

    Internal Medicine
    8 years experience
    Detroit, MI

    Dr. Nitin Mahajan

    Internal Medicine
    10 years experience
    Detroit, MI

    Dr. Timothy Byrnes

    Internal Medicine
    37 years experience
    Detroit, MI
    Search All Similar Doctors